Css attributes

.css-12qhwz2{background:url(https://backend.arctic-bioscience.com/wp-content/uploads/2021/04/cloud-download.png) no-repeat;float:left;width:24px;height :24px;margin-right:10px;}Presentation – ABS Capital Market Update September 21, 2022







arctic bioscience

Company presentation

Capital Markets Update, Oslo September 21, 2022

Christer L. Valderhaug (CEO)

Develop and market pharmaceutical and nutraceutical products based on unique bioactive marine compoundsusing proprietary technology and methodology

Agenda

  • Presentation and presentation of the company Christer Valderhaug, CEO of Arctic Bioscience
  • Psoriasis symptom relief with herring caviar oil Dr Kåre Steinar Tveit, Chief Physician at Haukeland University Hospital
  • Arctic Bioscience Pharmaceutical Development Program Runhild Gammelsæter, Medical Director Arctic Bioscience
  • Brain development in very preterm babies Knut Smerud, Founder and CEO Smerud Medical Research
  • DHA, Alfa & Omega for the brain Ole Petter Hjelle, MD PhD
  • Closing remarks and Q&A CEO Christer Valderhaug, Medical Director Runhild Gammelsæter, CFO Jone Slinning
  • lunch and social

Two unique companies built on proprietary technology and an IP platform

NUTRA

Premium omega-3 products with benefits for brain, heart, eye health, prenatal and sports nutrition in global markets

PHARMACY

Drug candidate for mild to moderate psoriasis with promising effect demonstrated in pilot clinical trial

Orphan drug candidate in development for brain development in extremely preterm infants

TECHNOLOGY / R&D

Proprietary technology platform and specialized know-how in bioactive marine compounds

Founding Story: Arctic Bioscience

2011-2016: laying the foundations

2011

2012

Arctic Bioscience is

Pharmaceutical

based

product potential

discovered

2017-2022: Building the basic framework for a strong clinical program

2017

2019

2020

2020

Pilot clinic

Pilot clinic

First clinic

Scientific

lawsuit launched

test

study results

Advice from

completed

published

EMA

2021

2022

Strategic

B2C

Dr Mercola

Initial Public Offering

HRO350

Partnership

B2B group sales

subscription is

passes for sales in the United States

entered with

exceed NOK

launched in

3m singles

Euronext

Phase IIb

Kotler

20m

Norway

order

Growth, Oslo

Nutra Scaling

2019

2019

2020

2020

worldwide

2019-2022: Evolve the organization to prepare for future growth

This is an excerpt from the original content. To continue reading it, access the original document here.

Disclaimer

Arctic Bioscience SA published this content on September 21, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on September 21, 2022 10:49:05 AM UTC.

Public now 2022

All news about ARCTIC BIOSCIENCE AS

2022 sales 37.0 million
3.59 million
3.59 million
Net income 2022 -37.8M
-3.66M
-3.66M
Net cash 2022 132 million
12.8 million
12.8 million
PER 2022 ratio -8.85x
2022 return
Capitalization 317M
30.7 million
30.7 million
EV / Sales 2022 4.99x
EV / Sales 2023 3.05x
# of employees 13
Floating 42.6%

Chart ARCTIC BIOSCIENCE AS


Duration :

Period :




Arctic Bioscience AS Technical Analysis Chart |  MarketScreener

Trending Technical Analysis ARCTIC BIOSCIENCE AS

Short term Middle term Long term
Tendencies Bearish Bearish Bearish




Evolution of the income statement

Sale

To buy

Medium consensus HOLD
Number of analysts 1
Last closing price NOK13.00
Average target price NOK15.00
Average Spread / Target 15.4%